Moreover, 2-BP treatment relieved EGFR palmitoylation and attenuated EGFR protein upregulation under NAFLD condition (Fig. 4G, H), which indicated that palmitoylation might contribute to EGFR protein upregulation in the NAFLD metabolic microenvironment. This evidence concerns the gene EGFR and metabolic dysfunction-associated steatotic liver disease.